■如何全面评估药物使用的合理性是一个具有挑战性的问题。
■建立tislelizumab有效使用的评价指标,从而保证其在临床应用中具有较高的合理性和规范性。
■根据指示,药物说明,和《国家基本医疗保险限制目录》的相关指南,我们对2022年1月至12月在我院使用tislelizumab注射液的286例患者进行了回顾性分析和评价,这些患者采用加权技术按相似度-理想解(TOPSIS)的偏好顺序法.
■在评估的286个病历中,主要的非理性表现是不适当的适应症(90例,31.47%),辅助检查和实验室检查不符合联合化疗药物的最低要求(40例,13.99%),药物疗程不规范(39例,13.64%)。在包括的案件中,57.34%是合理的情况(Ci^0.8),10.84%为基本合理案例(0.6Ci<0.8),不合理病例占31.82%(Ci<0.6)。
■TOPSIS方法,利用其属性层次模型(AHM)加权方法,可用作Tislelizumab注射的合理评估技术。tislelizumab在我院的临床应用仍然不足,这需要进一步改进管理。
UNASSIGNED: How to comprehensively evaluate the rationality of drug use is a challenging issue.
UNASSIGNED: To establish the evaluation index of the effective use of tislelizumab, so as to ensure its higher rationality and normalization in clinical application.
UNASSIGNED: Based on the indications, drug instructions, and relevant guidelines of the National Basic Medical Insurance Restriction Catalogue, a retrospective analysis and evaluation of 286 cases of using tislelizumab injection in our hospital from January to December 2022 were conducted using the weighted technique for order of preference by similarity to ideal solution (TOPSIS) method.
UNASSIGNED: Among the 286 medical records evaluated, the main irrational manifestations were inappropriate indications (90 cases, 31.47%), auxiliary examination and laboratory examination did not meet the minimum requirements of combination chemotherapy drugs (40 cases, 13.99%), the drug course was not standard (39 cases, 13.64%). Among the included cases, 57.34% were reasonable cases (Ci⩾ 0.8), 10.84% were basic reasonable cases (0.6 ⩽Ci< 0.8), and 31.82% were unreasonable cases (Ci< 0.6).
UNASSIGNED: The TOPSIS method, with its attribute hierarchical model (AHM)-weighted approach, can be employed as the rational assessment technique for the injection of tislelizumab. The clinical application of tislelizumab in our hospital is still insufficient, which needs to be further improved management.